Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Letter to the Editor

Letter regarding “Hepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessation”

Yun-Fan Liaw

Clin Mol Hepatol. 2024;30(2):269-271. Published online January 31, 2024

DOI: https://doi.org/10.3350/cmh.2024.0064

View: 1570 Download: 32 Web of Science: 1 Crossref: 1

Tsubasa Tsutsumi, Dan Nakano, Machiko Kawaguchi, Hirokazu Takahashi, Takumi Kawaguchi

Clin Mol Hepatol. 2024;30(2):266-268. Published online January 30, 2024

DOI: https://doi.org/10.3350/cmh.2024.0028

View: 1733 Download: 42 Crossref: 1

Changing from NAFLD to MASLD: Similar prognosis of patients with HCC under atezolizumab/bevacizumab treatment between NAFLD and MASLD

Hiroyuki Suzuki, Shigeo Shimose, Hideki Iwamoto, Takashi Niizeki, Takumi Kawaguchi

Clin Mol Hepatol. 2024;30(2):263-265. Published online January 18, 2024

DOI: https://doi.org/10.3350/cmh.2023.0557

View: 2091 Download: 122 Web of Science: 3 Crossref: 5

Original Article

Identification of signature gene set as highly accurate determination of metabolic dysfunction-associated steatotic liver disease progression

Sumin Oh, Yang-Hyun Baek, Sungju Jung, Sumin Yoon, Byeonggeun Kang, Su-hyang Han, Gaeul Park, Je Yeong Ko, Sang-Young Han, Jin-Sook Jeong, Jin-Han Cho, Young-Hoon Roh, Sung-Wook Lee, Gi-Bok Choi, Yong Sun Lee, Won Kim, Rho Hyun Seong, Jong Hoon Park, Yeon-Su Lee, Kyung Hyun Yoo

Clin Mol Hepatol. 2024;30(2):247-262. Published online January 26, 2024

DOI: https://doi.org/10.3350/cmh.2023.0449

View: 2881 Download: 201 Web of Science: 2 Crossref: 2

Global incidence of adverse clinical events in non-alcoholic fatty liver disease: A systematic review and meta-analysis

Michael H. Le, David M. Le, Thomas C. Baez, Hansen Dang, Vy H. Nguyen, KeeSeok Lee, Christopher D. Stave, Takanori Ito, Yuankai Wu, Yee Hui Yeo, Fanpu Ji, Ramsey Cheung, Mindie H. Nguyen

Clin Mol Hepatol. 2024;30(2):235-246. Published online January 26, 2024

DOI: https://doi.org/10.3350/cmh.2023.0485

View: 3577 Download: 229 Web of Science: 3 Crossref: 4

Prognosis of biopsy-confirmed metabolic dysfunction- associated steatotic liver disease: A sub-analysis of the CLIONE study

Michihiro Iwaki, Hideki Fujii, Hideki Hayashi, Hidenori Toyoda, Satoshi Oeda, Hideyuki Hyogo, Miwa Kawanaka, Asahiro Morishita, Kensuke Munekage, Kazuhito Kawata, Tsubasa Tsutsumi, Koji Sawada, Tatsuji Maeshiro, Hiroshi Tobita, Yuichi Yoshida, Masafumi Naito, Asuka Araki, Shingo Arakaki, Takumi Kawaguchi, Hidenao Noritake, Masafumi Ono, Tsutomu Masaki, Satoshi Yasuda, Eiichi Tomita, Masato Yoneda, Akihiro Tokushige, Yoshihiro Kamada, Hirokazu Takahashi, Shinichiro Ueda, Shinichi Aishima, Yoshio Sumida, Atsushi Nakajima, Takeshi Okanoue

Clin Mol Hepatol. 2024;30(2):225-234. Published online January 24, 2024

DOI: https://doi.org/10.3350/cmh.2023.0515

View: 3352 Download: 194 Web of Science: 4 Crossref: 4

JCAD deficiency attenuates activation of hepatic stellate cells and cholestatic fibrosis

Li Xie, Hui Chen, Li Zhang, Yue Ma, Yuan Zhou, Yong-Yu Yang, Chang Liu, Yu-Li Wang, Ya-Jun Yan, Jia Ding, Xiao Teng, Qiang Yang, Xiu-Ping Liu, Jian Wu

Clin Mol Hepatol. 2024;30(2):206-224. Published online January 8, 2024

DOI: https://doi.org/10.3350/cmh.2023.0506

View: 3410 Download: 187 Web of Science: 4 Crossref: 4

Efficacy, safety, and pharmacokinetics of capsid assembly modulator linvencorvir plus standard of care in chronic hepatitis B patients

Jinlin Hou, Edward Gane, Rozalina Balabanska, Wenhong Zhang, Jiming Zhang, Tien Huey Lim, Qing Xie, Chau-Ting Yeh, Sheng-Shun Yang, Xieer Liang, Piyawat Komolmit, Apinya Leerapun, Zenghui Xue, Ethan Chen, Yuchen Zhang, Qiaoqiao Xie, Ting-Tsung Chang, Tsung-Hui Hu, Seng Gee Lim, Wan-Long Chuang, Barbara Leggett, Qingyan Bo, Xue Zhou, Miriam Triyatni, Wen Zhang, Man-Fung Yuen

Clin Mol Hepatol. 2024;30(2):191-205. Published online January 8, 2024

DOI: https://doi.org/10.3350/cmh.2023.0422

View: 2884 Download: 176 Web of Science: 1 Crossref: 1

Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment

Miguel Sogbe, Idoia Bilbao, Francesco P. Marchese, Jon Zazpe, Annarosaria De Vito, Marta Pozuelo, Delia D’Avola, Mercedes Iñarrairaegui, Carmen Berasain, Maria Arechederra, Josepmaria Argemi, Bruno Sangro

Clin Mol Hepatol. 2024;30(2):177-190. Published online December 29, 2023

DOI: https://doi.org/10.3350/cmh.2023.0426

View: 6887 Download: 262 Web of Science: 2 Crossref: 2

Editorial

The gene expression signature of metabolic dysfunction- associated steatotic liver disease from a multiomics perspective

Carlos Jose Pirola, Silvia Sookoian

Clin Mol Hepatol. 2024;30(2):174-176. Published online February 5, 2024

DOI: https://doi.org/10.3350/cmh.2024.0082

View: 1937 Download: 59 Web of Science: 1 Crossref: 1

Steatotic liver disease: Know your enemies

Lung-Yi Mak

Clin Mol Hepatol. 2024;30(2):171-173. Published online February 2, 2024

DOI: https://doi.org/10.3350/cmh.2024.0078

View: 1887 Download: 70 Web of Science: 1 Crossref: 1

Clinical impact of five cardiometabolic risk factors in metabolic dysfunction-associated steatotic liver disease (MASLD): Insights into regional and ethnic differences

Joo Hyun Oh, Dae Won Jun

Clin Mol Hepatol. 2024;30(2):168-170. Published online March 5, 2024

DOI: https://doi.org/10.3350/cmh.2024.0140

View: 1984 Download: 63 Web of Science: 1 Crossref: 1

JCAD, a new potential therapeutic target in cholestatic liver disease

Byoung Kuk Jang

Clin Mol Hepatol. 2024;30(2):166-167. Published online March 8, 2024

DOI: https://doi.org/10.3350/cmh.2024.0128

View: 1805 Download: 39 Web of Science: 1 Crossref: 1

Linvencovir: Paving the way for functional cure in hepatitis B

Jiwon Yang, Jonggi Choi

Clin Mol Hepatol. 2024;30(2):164-165. Published online March 6, 2024

DOI: https://doi.org/10.3350/cmh.2024.0149

View: 1845 Download: 53

Exploring the prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma

Ji Eun Han, Hyo Jung Cho

Clin Mol Hepatol. 2024;30(2):160-163. Published online February 28, 2024

DOI: https://doi.org/10.3350/cmh.2024.0141

View: 1898 Download: 49

Evaluation of the histological scoring systems of autoimmune hepatitis: A significant step towards the optimization of clinical diagnosis

Atsumasa Komori

Clin Mol Hepatol. 2024;30(2):157-159. Published online February 23, 2024

DOI: https://doi.org/10.3350/cmh.2024.0131

View: 1852 Download: 63 Crossref: 2

Enhancing off-nucleos(t)ide analogue outcome predictions in chronic hepatitis B with time-varying hepatitis B core-related antigen

Chen-Te Huang, Tai-Chung Tseng

Clin Mol Hepatol. 2024;30(2):154-156. Published online February 22, 2024

DOI: https://doi.org/10.3350/cmh.2024.0120

View: 1660 Download: 50 Crossref: 1

Starting the journey: Understanding the roles of complement proteins in liver diseases through mendelian randomization

Mohammad Saeid Rezaee-Zavareh, Naomy Kim, Ju Dong Yang

Clin Mol Hepatol. 2024;30(2):150-153. Published online February 22, 2024

DOI: https://doi.org/10.3350/cmh.2024.0116

View: 2495 Download: 71 Web of Science: 1 Crossref: 1

Toward hepatitis C virus elimination using artificial intelligence

Moon Haeng Hur, Jeong-Hoon Lee

Clin Mol Hepatol. 2024;30(2):147-149. Published online February 23, 2024

DOI: https://doi.org/10.3350/cmh.2024.0135

View: 1965 Download: 67 Crossref: 1

Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide in patients with chronic hepatitis B: More questions than an answer

Pin-Nan Cheng, Ming-Lung Yu

Clin Mol Hepatol. 2024;30(2):144-146. Published online February 19, 2024

DOI: https://doi.org/10.3350/cmh.2024.0115

View: 1962 Download: 74 Crossref: 2

Review

Comprehensive approach to controlling chronic hepatitis B in China

Shan Shan, Xinyan Zhao, Jidong Jia

Clin Mol Hepatol. 2024;30(2):135-143. Published online January 5, 2024

DOI: https://doi.org/10.3350/cmh.2023.0412

View: 2742 Download: 184

Erratum

Erratum to ‘Correspondence on Letter regarding “Evidence-based hyponatremia management in liver disease”’ [Clin Mol Hepatol 2023;29:1048-1049]

Seon Ha Baek, Ji Young Ryu, Sejoong Kim

Clin Mol Hepatol. 2024;30(1):134-134. Published online November 7, 2023

DOI: https://doi.org/10.3350/cmh.2023.0261e
Corrects: Clin Mol Hepatol 2023;29(4):1048

View: 1283 Download: 26

Snapshot

Recent updates on pharmacologic therapy in non-alcoholic fatty liver disease

Young Chang, Soung Won Jeong, Jae Young Jang

Clin Mol Hepatol. 2024;30(1):129-133. Published online October 13, 2023

DOI: https://doi.org/10.3350/cmh.2023.0356

View: 2265 Download: 127 Crossref: 2

Correspondence

Correspondence on Letter regarding “Waiting for the changes after the adoption of steatotic liver disease”

Eileen L. Yoon, Dae Won Jun

Clin Mol Hepatol. 2024;30(1):126-128. Published online November 28, 2023

DOI: https://doi.org/10.3350/cmh.2023.0500

View: 1388 Download: 38

Correspondence on Letter regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”

Yee Hui Yeo, Ju Dong Yang

Clin Mol Hepatol. 2024;30(1):124-125. Published online November 14, 2023

DOI: https://doi.org/10.3350/cmh.2023.0470

View: 1376 Download: 40 Crossref: 1

Letter to the Editor

Changing from NAFLD to MASLD: Similar cumulative incidence of reflux esophagitis between NAFLD and MASLD

Shuhei Fukunaga, Michita Mukasa, Dan Nakano, Tsubasa Tsutsumi, Takumi Kawaguchi

Clin Mol Hepatol. 2024;30(1):121-123. Published online December 4, 2023

DOI: https://doi.org/10.3350/cmh.2023.0437

View: 1622 Download: 73 Web of Science: 5 Crossref: 2

Letter regarding “Waiting for the changes after the adoption of steatotic liver disease”

Kuo Chao Yew, Sunny H. Wong, Vincent Wai-Sun Wong, Hazel H. Oon

Clin Mol Hepatol. 2024;30(1):118-120. Published online November 14, 2023

DOI: https://doi.org/10.3350/cmh.2023.0472

View: 1918 Download: 49 Web of Science: 2 Crossref: 1

Letter 2 regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”

Yiwen Zhang, Liwei Wu, Zepeng Mu, Linlin Ren, Ying Chen, Hanyun Liu, Lili Xu, Yangang Wang, Yaxing Wang, Susan Cheng, Yih Chung Tham, Bin Sheng, Tien Yin Wong, Hongwei Ji

Clin Mol Hepatol. 2024;30(1):113-117. Published online November 10, 2023

DOI: https://doi.org/10.3350/cmh.2023.0440

View: 1691 Download: 67 Web of Science: 1 Crossref: 1

Letter 1 regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”

Hinpetch Daungsupawong, Viroj Wiwanitkit

Clin Mol Hepatol. 2024;30(1):111-112. Published online October 13, 2023

DOI: https://doi.org/10.3350/cmh.2023.0394

View: 1578 Download: 52

Letter regarding “Treated chronic hepatitis B is a good prognostic factor of diffuse large B-cell lymphoma”

Chi Hsiao, Yung-Po Liaw

Clin Mol Hepatol. 2024;30(1):109-110. Published online October 11, 2023

DOI: https://doi.org/10.3350/cmh.2023.0373

View: 1358 Download: 35

Viewed By 5504	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 5404	MAFLD: How is it different from NAFLD?
Viewed By 5214	Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
Viewed By 5094	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4725	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 176	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 113	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 108	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 90	MAFLD: How is it different from NAFLD?
Cited By 80	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Topics